TY - JOUR
T1 - Single-use duodenoscope for ERCP performed by endoscopists with a range of experience in procedures of variable complexity
AU - EXALT Single-use Duodenoscope Study Group
AU - Slivka, Adam
AU - Ross, Andrew S.
AU - Sejpal, Divyesh V.
AU - Petersen, Bret T.
AU - Bruno, Marco J.
AU - Pleskow, Douglas K.
AU - Muthusamy, V. Raman
AU - Chennat, Jennifer S.
AU - Krishnamoorthi, Rajesh
AU - Lee, Calvin
AU - Martin, John A.
AU - Poley, Jan Werner
AU - Cohen, Jonah M.
AU - Thaker, Adarsh M.
AU - Peetermans, Joyce A.
AU - Rousseau, Matthew J.
AU - Tirrell, Gregory P.
AU - Kozarek, Richard A.
AU - Khalid, Asif
AU - Das, Rohit
AU - Singh, Harkirat
AU - Vipperla, Kishore
AU - Antony, Andrew
AU - Choi, Jun Ho
AU - Larsen, Michael
AU - Law, Joanna
AU - Klair, Jagpal
AU - Thaker, Adarsh
AU - Abu Dayyeh, Barham
AU - Chandrasekhara, Vinay
AU - Levy, Michael
AU - Law, Ryan
AU - Insull, Jeff
N1 - Funding Information:
DISCLOSURE: The following authors disclosed financial relationships: A. Slivka: Research funding from Boston Scientific Corporation and Olympus. A. S. Ross: Consultant for and research funding from Boston Scientific Corporation. D. V. Sejpal: Consultant for Boston Scientific Corporation and Olympus; research funding from Boston Scientific Corporation. B. T. Petersen: Investigator for Boston Scientific Corporation; consultant for Olympus America and Ambu. M. J. Bruno: Research funding from Boston Scientific Corporation, Cook Medical, 3M, Pentax Medical, Mylan, and InterScope; consultant for Boston Scientific Corporation, Cook Medical, and Pentax Medical. D. K. Pleskow: Consultant for and research funding from Boston Scientific Corporation; consultant for Olympus, Fuji, and Medtronic. V. R. Muthusamy: Consultant for Boston Scientific Corporation, Medtronic, Medivators, and Interpace; research funding from Boston Scientific Corporation and Medtronic; honoraria from Ethicon/Torax; stockholder in CapsoVision. J.-W. Poley: Consultant for Boston Scientific Corporation, Cook Medical, and Pentax Medical. J. M. Cohen, A. M. Thaker: Consultant for Boston Scientific Corporation. J. A. Peetermans, M. J. Rousseau, G. P. Tirrell: Full-time employees of Boston Scientific Corporation. R. A. Kozarek: Research funding from Boston Scientific Corporation. All other authors disclosed no financial relationships. Research support for this study was provided by Boston Scientific Corporation.
Funding Information:
DISCLOSURE: The following authors disclosed financial relationships: A. Slivka: Research funding from Boston Scientific Corporation and Olympus. A. S. Ross: Consultant for and research funding from Boston Scientific Corporation. D. V. Sejpal: Consultant for Boston Scientific Corporation and Olympus; research funding from Boston Scientific Corporation. B. T. Petersen: Investigator for Boston Scientific Corporation; consultant for Olympus America and Ambu. M. J. Bruno: Research funding from Boston Scientific Corporation, Cook Medical, 3M, Pentax Medical, Mylan, and InterScope; consultant for Boston Scientific Corporation, Cook Medical, and Pentax Medical. D. K. Pleskow: Consultant for and research funding from Boston Scientific Corporation; consultant for Olympus, Fuji, and Medtronic. V. R. Muthusamy: Consultant for Boston Scientific Corporation, Medtronic, Medivators, and Interpace; research funding from Boston Scientific Corporation and Medtronic; honoraria from Ethicon/Torax; stockholder in CapsoVision. J.-W. Poley: Consultant for Boston Scientific Corporation, Cook Medical, and Pentax Medical. J. M. Cohen, A. M. Thaker: Consultant for Boston Scientific Corporation. J. A. Peetermans, M. J. Rousseau, G. P. Tirrell: Full-time employees of Boston Scientific Corporation. R. A. Kozarek: Research funding from Boston Scientific Corporation. All other authors disclosed no financial relationships. Research support for this study was provided by Boston Scientific Corporation.
Publisher Copyright:
© 2021 American Society for Gastrointestinal Endoscopy
PY - 2021/12
Y1 - 2021/12
N2 - Background and Aims: Expert endoscopists previously reported ERCP outcomes for the first commercialized single-use duodenoscope. We aimed to document usability of this device by endoscopists with different levels of ERCP experience. Methods: Fourteen “expert” (>2000 lifetime ERCPs) and 5 “less-expert” endoscopists performed consecutive ERCPs in patients without altered pancreaticobiliary anatomy. Outcomes included ERCP completion for the intended indication, rate of crossover to another endoscope, device performance ratings, and serious adverse events. Results: Two hundred ERCPs including 81 (40.5%) with high complexity (American Society for Gastrointestinal Endoscopy grades 3-4) were performed. Crossover rate (11.3% vs 2.5%, P =.131), ERCP completion rate (regardless of crossovers) (96.3% vs 97.5%, P =.999), median ERCP completion time (25.0 vs 28.5 minutes, P =.130), mean cannulation attempts (2.8 vs 2.8, P =.954), and median overall satisfaction with the single-use duodenoscope (8.0 vs 8.0 [range, 1.0-10.0], P =.840) were similar for expert versus less-expert endoscopists, respectively. The same metrics were similar by procedural complexity except for shorter median completion time for grades 1 to 2 versus grades 3 to 4 (P <.001). Serious adverse events were reported in 13 patients (6.5%). Conclusions: In consecutive ERCPs including high complexity procedures, endoscopists with varying ERCP experience had good procedural success and reported high device performance ratings. (Clinical trial registration number: NCT04223830.)
AB - Background and Aims: Expert endoscopists previously reported ERCP outcomes for the first commercialized single-use duodenoscope. We aimed to document usability of this device by endoscopists with different levels of ERCP experience. Methods: Fourteen “expert” (>2000 lifetime ERCPs) and 5 “less-expert” endoscopists performed consecutive ERCPs in patients without altered pancreaticobiliary anatomy. Outcomes included ERCP completion for the intended indication, rate of crossover to another endoscope, device performance ratings, and serious adverse events. Results: Two hundred ERCPs including 81 (40.5%) with high complexity (American Society for Gastrointestinal Endoscopy grades 3-4) were performed. Crossover rate (11.3% vs 2.5%, P =.131), ERCP completion rate (regardless of crossovers) (96.3% vs 97.5%, P =.999), median ERCP completion time (25.0 vs 28.5 minutes, P =.130), mean cannulation attempts (2.8 vs 2.8, P =.954), and median overall satisfaction with the single-use duodenoscope (8.0 vs 8.0 [range, 1.0-10.0], P =.840) were similar for expert versus less-expert endoscopists, respectively. The same metrics were similar by procedural complexity except for shorter median completion time for grades 1 to 2 versus grades 3 to 4 (P <.001). Serious adverse events were reported in 13 patients (6.5%). Conclusions: In consecutive ERCPs including high complexity procedures, endoscopists with varying ERCP experience had good procedural success and reported high device performance ratings. (Clinical trial registration number: NCT04223830.)
UR - http://www.scopus.com/inward/record.url?scp=85114988821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114988821&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2021.06.017
DO - 10.1016/j.gie.2021.06.017
M3 - Article
C2 - 34186052
AN - SCOPUS:85114988821
SN - 0016-5107
VL - 94
SP - 1046
EP - 1055
JO - Gastrointestinal endoscopy
JF - Gastrointestinal endoscopy
IS - 6
ER -